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What's hot that the other 
lot got
J elshof1,2
Domiciliary nasal high-floW 
therapy in stable hypoxic copD 
patients
Nasal high-flow (NHF) therapy has 
been shown to be a beneficial therapy 
for patients with acute respiratory 
failure in hospital and might be benefi-
cial in patients with chronic hypoxemic 
respiratory failure if delivered at home. 
Storgaard et al. (Int J Chron Obstruct 
Pulmon Dis 2018;13:1195) performed 
a randomised controlled trial comparing 
NHF added to long-term oxygen therapy 
(LTOT+NHF) to LTOT alone in 200 
moderately severe COPD patients. 
Compared with the previous year, 
patient-reported exacerbations increased 
from 2.90 to 4.95/patient/year in the 
LTOT alone group compared with a slight 
decrease from 3.23 to 3.12/patient/year 
in the LTOT+NHF group, resulting in a 
lower exacerbation frequency in the NHF 
group compared with the LTOT group 
(p<0.001). However, hospital admission 
and all-cause mortality were not different 
between the groups after 1 year. Explor-
atory analyses suggested that there was a 
dose response effect with a reduction in 
admissions in patients with high device 
usage. Furthermore, dyspnoea symp-
toms, health-related quality of life, arte-
rial carbon dioxide pressure (PaCO2), and 
the 6 min walking distance improved in 
the NHF group compared with the LTOT 
group (all p<0.001). The study demon-
strates that NHF is a potentially viable 
therapy in the home setting and may 
have physiological and clinical impact in 
patients with COPD on LTOT. Future 
studies should focus on high risk patients 
to assess the potential clinical impact on 
admission reduction.
CO2 ClearanCe with nasal high-flOw 
therapy in hyperCapniC COpD patients 
is flOw anD leak DepenDent
Studies have shown that nasal high-
flow (NHF) therapy might reduce arte-
rial PaCO2 in stable hypercapnic COPD 
patients. Possible mechanisms include 
an increase in airway pressure or a 
washout of the upper airways. Bräunlich 
et al. (BMC Pulm Med 2018;18.1:14) 
conducted a study to evaluate these 
mechanisms. Hypercapnia was evaluated 
in 36 COPD patients by capillary blood 
gas sampling before and 1 hour after 
NHF therapy under four conditions with 
different effective flow rates and degrees 
of leakage achieved by varying nasal prong 
position (A=20 L/min with low leakage; 
B=40 L/min with low leakage; C=20 
L/min with high leakage; D=40 L/min 
with high leakage). In 10 COPD patients, 
mean airway pressure was measured in 
the nasopharynx under identical condi-
tions. NHF reduced capillary PCO2 in all 
patients, without significant differences 
between the four conditions (~5% reduc-
tion). In patients with a baseline capil-
lary PCO2 >55 mmHg (n=26), capillary 
PCO2 decrease was dependent on leak 
and flow levels (percentage of baseline 
capillary PCO2±SD: A=94.2%±8.2%; 
B=93.5%±4.4%; C=90.5±7.2%; 
D=86.8%±3.8%). The highest mean 
airway pressure was achieved under condi-
tion B (2.3±1.6 mbar), while the lowest 
PCO2 was observed in condition D, indi-
cating that change in airway pressure was 
not related to change in capillary PCO2 
but rather that washout of the dead space 
area is the principal working mechanism 
of NHF in this patient group. These data 
will help support the design of future trials 
and clinical practice by ensuring better 
understanding of optimal device settings.
non-invasive ventilation During 
exercise training
Non-invasive ventilation (NIV) added 
to exercise training (ET) improves 
the intensity at which patients with 
COPD can exercise. However, there 
are no data showing NIV added to ET 
improves health-related quality of life 
(HRQoL) or clinical parameters in 
patients with chronic respiratory failure 
(CRF) secondary to either obstructive 
or restrictive lung disease. Vitacca et al. 
(Respirology 2018;23.2:182–189) inves-
tigated whether adding NIV during ET 
could increase the 6 min walking distance 
(6MWD) compared with ET alone in 
patients with CRF already treated with 
home NIV. The trial was powered based 
on a doubling of the effect of ET on 
6MWD with additional NIV. Fifty patients 
with COPD or a restrictive lung disease 
were randomly assigned to ET with NIV 
(delivered at their home NIV settings) 
or ET alone. All patients underwent 20 
sessions of cycle training over a 3 week 
period. The 6MWD improved above the 
minimum clinically important difference 
(MCID=25 m) in both groups (ET+NIV: 
299 to 344 m (p=0.004); ET alone: 
315 to 359 m (p=0.0002)), without a 
between group difference. Improvement 
in cycle endurance time was significantly 
greater in the NIV group (754±974 s vs 
51±407 s (MCID=200 s), p=0.0271), 
although with significant heteroge-
neity. Of note HRQoL improved only 
in the control group. Only one patient 
dropped-out because of NIV intolerance 
during training. Unfortunately, the study 
lasted only 3 weeks and it is unknown 
whether the used NIV pressures during 
ET were sufficient to unload the respi-
ratory muscles. Despite demonstrating 
the feasibility and physiological benefits 
of adding NIV to exercise training in 
patients with chronic respiratory failure 
there was no evidence of improvement in 
clinically meaningful endpoints such as 
HRQoL or 6MWD. Whether this relates 
to failure to optimise the intervention by 
delivering targeted NIV settings or due 
to under powering of the trial is unclear.
non-invasive ventilation in 
patients With bulbar amyotrophic 
lateral sclerosis
The efficacy of non-invasive ventila-
tion in Amyotrophic Lateral Sclerosis 
(ALS) patients with bulbar dysfunction is 
not clear. Sancho et al. (ERJ Open Res 
2018;4.2:00 159–2017 investigated the 
effect of NIV on survival of ALS patients 
in relation to the degree of bulbar 
dysfunction and determined prognostic 
factors associated with NIV failure. The 
study utilised a prospective non-ran-
domised design with all ALS patients 
attending a specialist centre in whom NIV 
was indicated being enrolled. Patients 
were divided into groups; those who 
agreed to NIV treatment and were NIV 
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tolerant (n=120) and a control group 
of patients who refused NIV without 
any attempt at acclimatisation (n=20). 
Patients who tried and failed NIV were 
excluded. The NIV group survived 
longer compared with the control group 
(18 months vs 3 months, p<0.001). The 
survival advantage conferred by NIV 
persisted in patients with severe bulbar 
dysfunction (13 months vs 3 months, 
p<0.001). Nevertheless, having severe 
bulbar dysfunction at NIV initiation was 
prognostically unfavourable. Survival in 
the non-bulbar patients on NIV was 20 
months vs 13 months in patients with 
bulbar dysfunction (HR 0.5, p=0.001). 
The control of sleep disordered breathing 
as measured by %sleep time SpO2<90% 
while using NIV was also found to be 
prognostic factor (HR 1.12, p=0.02). 
The study will provide further infor-
mation for clinicians caring for patients 
with ALS supporting the individualising 
of management decisions, in particular 
suggesting that severe bulbar dysfunction 
in ALS should not be a barrier to delivery 
of NIV and that titration of NIV may be 
important to maximise efficacy.
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